Brian Saccente-Kennedy

Brian Saccente-Kennedy

Auto-generated profile, based on publicly available information

Brian Saccente-Kennedy

Department of Speech and Language Therapy (ENT), Royal National Ear, Nose and Throat and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Aerosol Science and Technology
Verified
Journal Article
Open access
JHJoshua Harrison
Joshua Harrison
BSBrian Saccente-Kennedy
Brian Saccente-Kennedy
COChristopher M. Orton
Christopher M. Orton
LMLauren P. McCarthy
Lauren P. McCarthy
JAJustice Archer
Justice Archer
BBBryan R. Bzdek
Bryan R. Bzdek
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought renewed attention to respiratory aerosol and droplet generation. While many studies have robustly quantified aerosol (20 µm diameter) generated by a cohort of 76 adults and children using a water-sensitive paper droplet deposition approach. Unvoiced and voiced activities spanning different levels of loudness, different lengths of sustained phonation, and a specific manner of articulation in isolation were investigated. We find that oral articulation drives >20 µm droplet generation, with breathing generating virtually no droplets and speaking and singing generating on the order of 250 droplets min−1. Lip trilling, which requires extensive oral articulation, generated the most droplets, whereas shouting “Hey”, which requires minimal oral articulation, generated relatively few droplets. Droplet size distributions were all broadly consistent, and no significant differences between the children and adult cohorts were identified. By comparing the aerosol and droplet emissions for the same participants, the full size distribution of respiratory aerosol (0.5-1000 µm) is reported. Although 20 µm droplets dominate the mass concentration. Accurate quantification of aerosol concentrations in the 10-70 μm size range remains very challenging; more robust aerosol analysis approaches are needed to characterize this size range. Graphical Abstract

8 January 2024 in Journal of Voice
Verified
Journal Article
Closed access
BSBrian Saccente-Kennedy
Brian Saccente-Kennedy
FGFiona Gillies
Fiona Gillies
MDMaude Desjardins
Maude Desjardins
JSJarrad Van Stan
Jarrad Van Stan
RGRoganie Govender
Roganie Govender

3 November 2023 in Aerosol Science and Technology
Verified
Journal Article
Open access
ASAlicja Szczepanska
Alicja Szczepanska
JHJoshua Harrison
Joshua Harrison
BSBrian Saccente-Kennedy
Brian Saccente-Kennedy
JAJustice Archer
Justice Archer
NWNatalie A. Watson
Natalie A. Watson
JRJonathan Reid
Jonathan Reid

29 May 2023 in Clinical Otolaryngology
Verified
Journal Article
Open access
NHNick J. I. Hamilton
Nick J. I. Hamilton
BSBrian Saccente‐Kennedy
Brian Saccente‐Kennedy
GAGareth Ambler
Gareth Ambler
ObjectivesThis systematic review and meta-analysis examines if intralaryngeal injection of basic fibroblast growth factor 2 (FGF2) can improve voice outcomes in those with vocal disability. DesignA Systematic review of original human studies reporting voice outcomes following intra-laryngeal injection of basic fibroblast growth factor 2 in those with vocal dysfunction. Databases searched were Medline (1946-July 2022), Embase (1947-July 2022), Cochrane database and Google Scholar. SettingSecondary or tertiary care centres that undertook the management of voice pathology Hospital. ParticipantsInclusion criteria were original human studies reporting voice outcome measurements following intralaryngeal injection of FGF2 to treat vocal fold atrophy, vocal fold scarring, vocal fold sulcus or vocal fold palsy. Articles not written in English, studies that did not include human subjects and studies where voice outcome measures were not recorded before and after FGF2 injection were excluded from the review. Main Outcome MeasuresThe primary outcome measure was maximum phonation time. Secondary outcome measures included acoustic analysis, glottic closure, mucosal wave formation, voice handicap index and GRBAS scale. ResultsFourteen articles were included out of a search of 1023 and one article was included from scanning reference lists. All studies had a single arm design without control groups. Conditions treated were vocal fold atrophy (n = 186), vocal cord paralysis (n = 74), vocal fold fibrosis (n = 74) and vocal fold sulcus (n = 56). A meta-analysis of six articles reporting on the use of FGF2 in patients with vocal fold atrophy showed a significant increase of mean maximum phonation time of 5.2 s (95% CI: 3.4-7.0) at 3-6 months following injection. A significant improvement in maximum phonation time, voice handicap index and glottic closure was found following injection in most studies assessed. No major adverse events were reported following injection. ConclusionsTo date, intralaryngeal injection of basic FGF2 appears to be safe and it may be able to improve voice outcomes in those with vocal dysfunction, especially vocal fold atrophy. Randomised controlled trials are needed to further evaluate efficacy and support the wider use of this therapy.


27 May 2023 in Journal of Voice
Verified
Journal Article
Open access
BSBrian Saccente-Kennedy
Brian Saccente-Kennedy
ASAlicja Szczepanska
Alicja Szczepanska
JHJoshua Harrison
Joshua Harrison
JAJustice Archer
Justice Archer
NWNatalie A. Watson
Natalie A. Watson
RERuth Epstein
Ruth Epstein
Phonation and speech are known sources of respirable aerosol in humans. Voice assessment and treatment manipulate all the subsystems of voice production, and previous work (Saccente-Kennedy et al., 2022) has demonstrated such activities can generate >10 times more aerosol than conversational speech and 30 times more aerosol than breathing. Aspects of voice therapy may therefore be considered aerosol generating procedures and pose a greater risk of potential airborne pathogen (eg, SARS-CoV-2) transmission than typical speech. Effective mitigation measures may be required to ensure safe service delivery for therapist and patient. To assess the effectiveness of mitigation measures in reducing detectable respirable aerosol produced by voice assessment/therapy. We recruited 15 healthy participants (8 cis-males, 7 cis-females), 9 of whom were voice-specialist speech-language pathologists. Optical Particle Sizers (OPS) (Model 3330, TSI) were used to measure the number concentration of respirable aerosol particles (0.3 µm-10 µm) generated during a selection of voice assessment/therapy tasks, both with and without mitigation measures in place. Measurements were performed in a laminar flow operating theatre, with near-zero background aerosol concentration, allowing us to quantify the number concentration of respiratory aerosol particles produced. Mitigation measures included the wearing of Type IIR fluid resistant surgical masks, wrapping the same masks around the end of straws, and the use of heat and moisture exchange microbiological filters (HMEFs) for a water resistance therapy (WRT) task. All unmitigated therapy tasks produced more aerosol than unmasked breathing or speaking. Mitigation strategies reduced detectable aerosol from all tasks to a level significantly below, or no different to, that of unmasked breathing. Pooled filtration efficiencies determined that Type IIR surgical masks reduced detectable aerosol by 90%. Surgical masks wrapped around straws reduced detectable aerosol by 96%. HMEF filters were 100% effective in mitigating the aerosol from WRT, the exercise that generated more aerosol than any other task in the unmitigated condition. Voice therapy and assessment causes the release of significant quantities of respirable aerosol. However, simple mitigation strategies can reduce emitted aerosol concentrations to levels comparable to unmasked breathing.